Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RA Capital
Biotech
AltruBio raises $225M for midphase ulcerative colitis program
AltruBio has roared back after another pivot in its twisty history, securing $225 million to test an immune checkpoint enhancer in ulcerative colitis.
Nick Paul Taylor
May 21, 2024 8:00am
BMS-backed TORL grabs $158M to march army of ADCs through clinic
Apr 10, 2024 9:35am
Diagonal launches with $128M to grow agonist antibody platform
Apr 3, 2024 6:00am
Eliem cuts in on Tango, proposing acquisition after review
Mar 19, 2024 10:57am
Boundless Bio bumps IPO market back to life
Mar 6, 2024 5:20pm
VC investment in biopharma dropped nearly $7B in 2023: PitchBook
Mar 5, 2024 5:00am